查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2000757

微型RNA市場：全球市場按產品類型、技術、樣品來源、應用和最終用戶分類的預測 - 2026-2032年

microRNA Market by Product Type, Technology, Sample Source, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年， 微型RNA市場價值將達到 35 億美元，到 2026 年將成長至 45.1 億美元，到 2032 年將達到 218.5 億美元，複合年成長率為 29.88%。

主要市場統計數據
基準年 2025 35億美元
預計年份：2026年 45.1億美元
預測年份 2032 218.5億美元
複合年成長率 (%) 29.88%

這是一本權威的入門書籍，介紹了微型RNA的生物學、轉化潛力、基礎技術以及在研究和臨床環境中的戰略意義。

微型RNA生物學已從一個小眾學術領域發展成為分子調控的核心支柱，對研究、診斷和治療方法開發產生深遠影響。這些短鏈非編碼RNA在多種生物系統中調控轉錄後基因表達，其失調與腫瘤發生、心血管疾病、感染疾病反應、神經退化疾病直接相關。隨著研究人員和臨床醫生對微型RNA網路的理解不斷加深，相關技術也不斷發展，湧現出更多靈敏、特異性且可擴展的檢測方法，為基礎科學和轉化醫學研究提供了重要資訊。

定序技術、高靈敏度檢測、生物資訊整合以及合作商業化模式的進步正在推動微型RNA研究和應用發生重大變革。

近年來，在技術創新和不斷變化的臨床需求的雙重驅動下， 微型RNA科學的研究和應用正經歷著一場變革性的轉變。定序技術日趨普及且精細化，能夠更深入地覆蓋小RNA種類，並顯著提升對異構體和修飾的辨識能力。同時，精準擴增平台、標靶捕獲流程和混合方法提高了對生物體液中低表達微型RNA的檢測靈敏度，拓展了微創診斷的可能性。計算生物學的同步發展，包括基於機器學習的特徵選擇和整合的多組體學框架，正在提升微型RNA特徵的可解釋性和臨床相關性。

本研究評估了 2025 年美國關稅措施將如何重塑微型RNA研究和診斷領域的供應鏈、籌資策略和營運重點。

美國2025年宣布的關稅措施的累積影響，正在為整個微型RNA生態系統帶來一系列複雜的營運和策略壓力。對進口設備、關鍵試劑和特殊耗材徵收的關稅，正在推高實驗室和診斷開發公司的整體成本，並使採購週期更加複雜。這些壓力導致依賴全球供應鏈的學術機構、受託研究機構和診斷檢查室的前置作業時間延長，資本支出和營運成本增加。對於依賴跨境生產精密光學元件、微流體組件或特殊酵素的供應商而言，關稅正在擠壓利潤空間，迫使他們重新評估定價策略和生產地點。

關鍵細分洞察揭示了產品類型、應用領域和特定最終用戶群如何協作，以確定部署路徑和檢驗優先順序。

對產品、應用和最終用戶細分的深入理解揭示了整個微型RNA價值鏈中存在的差異化機會和實施挑戰。從產品角度來看，其範圍涵蓋儀器、試劑盒和試劑，以及軟體和服務。儀器包括微陣列系統、qPCR系統和定序系統，每種系統都具有其獨特的靈敏度和通量特徵。試劑盒和試劑包括檢測試劑盒、萃取試劑盒、樣品製備盒和分析試劑盒，這些試劑盒針對不同的樣本類型和工作流程而設計。軟體和服務包括生物資訊服務、諮詢服務以及將原始數據轉化為可操作結果的數據分析軟體。這些產品層面的差異影響著最終使用者的採用模式、檢驗需求和採購標準。

區域戰略觀點重點闡述美洲、歐洲、中東和非洲以及亞太地區如何影響採用、監管策略和商業化路徑。

區域趨勢對微型RNA相關舉措的採納、商業化和營運實施有顯著影響。在美洲，強大的學術網路、蓬勃發展的生物技術產業和完善的臨床試驗計劃正在加速轉化計畫的推進，但各機構必須應對不斷變化的報銷框架和供應鏈突發情況。歐洲、中東和非洲（EMEA）的情況則較為複雜，複雜的監管體系和公共衛生優先事項與生產能力和採購慣例的差異並存。泛歐聯盟協調標準和全部區域臨床檢驗舉措往往能帶來機會。在亞太地區，技術快速普及、對本地生產的大量投資以及不斷擴展的診斷服務網路正在興起，但相關人員正努力應對可能影響夥伴關係策略的各種監管方法和競爭激烈的本地供應商。

這顯示平台性能、試劑品質、生物資訊能力和服務整合如何影響微型RNA舉措的成功，突顯了企業層面的競爭與合作趨勢。

微型RNA生態系內的競爭動態呈現出多元化的態勢，既有成熟的儀器供應商，也有敏捷的試劑創新者、專業的生物資訊公司和綜合服務供應商。儀器供應商透過靈敏度、動態範圍和通量等分析性能特徵來區分自身，而試劑開發人員則在穩健性、批間一致性和易於整合到自動化工作流程等方面展開競爭。軟體和服務供應商透過提供檢驗的流程、符合監管要求的文件以及能夠將複雜資料集轉化為具有臨床意義的輸出結果的解讀層來創造價值。同時，受託研究機構（CRO）和診斷檢查室正在整合自身能力，專注於端到端的服務交付，以加速轉化檢測方法的檢驗和市場推廣。

為領導者提供具體的策略建議，以建立供應鏈韌性、實施模組化工作流程、優先考慮生物資訊學以及加快符合監管要求的檢驗。

產業領導者應採取務實且多管齊下的策略，兼顧短期韌性和長期價值創造。首先，他們應透過認證關鍵組件的多家供應商、探索區域製造夥伴關係關係以及為高優先試劑和耗材維持戰略安全庫存，來增強價值鏈韌性。其次，他們應優先投資於模組化、符合標準的流程，以便快速切換儀器平台和試劑化學成分，從而減少供應商鎖定並加快跨站點檢驗。第三，他們應透過採用可互通的數據標準、投資於可重複的流程以及開發臨床級報告模組來加強生物資訊學和數據管理能力，從而促進監管申報和臨床醫生應用。

結合文獻整合、專家訪談、績效檢驗和三角驗證的穩健混合調查方法，得出了有效且可操作的結論。

本分析的調查方法結合了對原始科學文獻的系統性回顧、對學術界、工業界和臨床檢查室專家的定向訪談，以及透過與獨立檢驗報告和監管指導文件進行比較來交叉檢驗技術性能特徵。該方法包括系統地梳理儀器功能、試劑性能參數和軟體互通性，然後進行情境分析，以評估在監管條件下對替代採購和操作的影響。在條件允許的情況下，研究結果透過多方面的證據進行檢驗，以確保其穩健性並揭示一致的模式，而非孤立的觀察。

一項權威的整合，重點闡述了技術進步、營運靈活性和策略夥伴關係如何融合，從而釋放微型RNA的轉化和商業性潛力。

總之， 微型RNA領域正處於科學成熟度、技術能力和商業性機會交會的十字路口。檢測技術、定序深度和計算分析的進步，使得可靠的生物標記得以發現，更穩健的診斷方法得以開發；同時，不斷變化的採購和法規環境也要求更高的營運彈性。積極應對供應鏈中斷、優先考慮互通性和檢驗的工作流程，並投資於臨床級生物資訊學的相關人員，將更有利於把科學知識轉化為檢驗的診斷和治療方法。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章微型RNA市場：依產品類型分類

  • 裝置
    • 微陣列系統
    • qPCR系統
    • 定序系統
  • 試劑盒和試劑
    • 檢測套件
    • 提取套件
    • 樣品製備工具包
    • 分析工具包
  • 軟體服務
    • 生物資訊服務
    • 諮詢服務
    • 數據分析軟體

第9章： 微型RNA市場：依技術分類

  • 聚合酵素鏈鎖反應
  • 雜合反應方法
    • 微陣列
    • 原位雜合反應
  • 定序鹼基
    • 次世代定序
    • 單分子定序
  • 印跡法和電泳法
  • 免疫檢測和報告技術

第10章：檢體來源分類的微型RNA市場

  • 組織樣本
  • 生物液體
    • 血
      • 血清
      • 電漿
    • 尿
    • 唾液
    • 腦脊髓液
  • 細胞株
    • 人類細胞株
    • 動物細胞株
    • 原代培養細胞
  • 外泌體和細胞外囊泡

第11章： 微型RNA市場：依應用分類

  • 基礎研究
    • 功能基因體學
    • 基因表現分析
  • 診斷
    • 癌症診斷
    • 心血管診斷
    • 感染疾病診斷
  • 藥物發現與開發
    • 生物標記發現
    • 目標檢驗
    • 毒性測試

第12章微型RNA市場：依最終用戶分類

  • 學術和研究機構
  • 合約研究機構
  • 診斷檢測實驗室
  • 製藥和生物技術公司

第13章： 微型RNA市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章微型RNA市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章微型RNA市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國微型RNA市場

第17章：中國微型RNA市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Agilent Technologies, Inc.
  • BioGenex Laboratories, Inc.
  • GeneCopoeia, Inc.
  • Horizon Discovery Group plc
  • Illumina, Inc.
  • InteRNA Technologies BV
  • Merck KGaA
  • Miltenyi Biotec GmbH
  • Mirxes Pte. Ltd.
  • NanoString Technologies, Inc.
  • New England Biolabs, Inc.
  • OriGene Technologies, Inc.
  • PerkinElmer, Inc.
  • QIAGEN NV
  • Quantabio, Inc.
  • Regulus Therapeutics Inc.
  • Takara Bio Inc.
  • Thermo Fisher Scientific Inc.
Product Code: MRR-02026C4C98C4

The microRNA Market was valued at USD 3.50 billion in 2025 and is projected to grow to USD 4.51 billion in 2026, with a CAGR of 29.88%, reaching USD 21.85 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 3.50 billion
Estimated Year [2026] USD 4.51 billion
Forecast Year [2032] USD 21.85 billion
CAGR (%) 29.88%

An authoritative introduction to microRNA biology, translational potential, enabling technologies, and strategic implications across research and clinical environments

MicroRNA biology has matured from a niche academic curiosity into a central pillar of molecular regulation with profound implications for research, diagnostics, and therapeutic development. These short, non-coding RNA species govern post-transcriptional gene regulation across diverse biological systems, and their dysregulation links directly to oncogenesis, cardiovascular pathology, infectious disease response, and neurodegenerative processes. As investigators and clinicians deepen their understanding of microRNA networks, the technology landscape has adapted to deliver increasingly sensitive, specific, and scalable detection modalities that inform both basic science and translational pipelines.

Consequently, stakeholders across academia, diagnostics, and industry now view microRNA analytics as both a discovery engine and a route to near-term clinical impact. The convergence of high-throughput sequencing, targeted amplification technologies, and advanced bioinformatics has lowered technical barriers and enabled new study designs, from population-level biomarker screens to single-cell and spatially resolved interrogations. As a result, investment priorities are shifting toward integrated solutions that pair robust wet-lab workflows with analytics platforms capable of handling multimodal data and regulatory-grade reporting, thereby turning mechanistic insights into actionable clinical and commercial outcomes.

Critical transformative shifts in microRNA research and application driven by sequencing advances, sensitive detection, bioinformatics integration, and collaborative commercialization models

Recent years have witnessed transformative shifts that are redefining how microRNA science is pursued and applied, driven by both technological innovation and evolving clinical needs. Sequencing technologies have become more accessible and nuanced, enabling deeper coverage of small RNA species and improved discrimination of isoforms and modifications. At the same time, precision amplification platforms, targeted capture workflows, and hybrid approaches have increased sensitivity for low-abundance microRNAs in biofluids, widening the possibilities for minimally invasive diagnostics. Parallel advances in computational biology, including machine learning-driven feature selection and integrative multi-omics frameworks, have increased the interpretability and clinical relevance of microRNA signatures.

Beyond instruments and algorithms, structural industry shifts are also evident. Collaboration models are evolving, with instrument vendors, reagent developers, bioinformatics providers, and clinical labs forming closer partnerships to expedite validation and commercialization. Regulatory agencies are clarifying expectations for nucleic acid-based assays, and payers are beginning to demand stronger evidence of clinical utility and cost-effectiveness. Taken together, these changes are accelerating the translation of microRNA discoveries into standardized assays and decision-support tools, while also raising the bar for data quality, reproducibility, and regulatory compliance.

Assessing how 2025 United States tariff measures are reshaping supply chains, procurement strategies, and operational priorities across the microRNA research and diagnostic landscape

The cumulative effect of United States tariff actions announced in 2025 has introduced a complex set of operational and strategic pressures across the microRNA ecosystem. Tariffs on imported instruments, critical reagents, and specialized consumables increase landed costs and complicate procurement cycles for laboratories and diagnostic developers. These pressures translate into longer lead times and higher capital and operating expenditures for academic institutions, contract research organizations, and diagnostic laboratories that depend on global supply chains. For vendors that rely on cross-border manufacturing of precision optics, microfluidic components, or specialty enzymes, tariffs create margin pressure and force reassessment of pricing strategies and production footprints.

In response to the new tariff environment, organizations are adopting mitigation strategies that include diversifying suppliers, expanding regional manufacturing partnerships, and implementing inventory and contract hedging practices. Some stakeholders are accelerating initiatives to localize critical components or to qualify alternative chemistries and platforms that reduce dependency on tariff-impacted imports. Meanwhile, research timelines can lengthen as procurement constraints delay instrument deployments and reagent availability, and collaborative projects may require revised contracting to reflect higher total costs. The aggregate impact is a shift in how project budgets are structured and prioritized, encouraging initiatives that deliver rapid technical validation and clear clinical value to justify adjusted investment levels under changed cost dynamics.

Key segmentation insights revealing how product types, application domains, and distinct end-user groups jointly determine adoption pathways and validation priorities

A granular understanding of product, application, and end-user segmentation reveals differentiated opportunities and execution challenges across the microRNA value chain. From a product perspective, the landscape spans instruments, kits and reagents, and software and services. Instrumentation includes microarray systems, qPCR systems, and sequencing systems, each offering distinct sensitivity profiles and throughput characteristics; kits and reagents comprise detection kits, extraction kits, library preparation kits, and profiling kits that are tailored to different sample types and workflows; and software and services encompass bioinformatics services, consultation services, and data analysis software that bridge raw data to actionable interpretation. These product-level distinctions shape adoption patterns, validation needs, and procurement criteria for end users.

In terms of application, functions bifurcate into basic research, diagnostics, and drug discovery and development. Within basic research, activities such as functional genomics and gene expression profiling rely on flexible platforms that prioritize breadth and experimental control. Diagnostic applications emphasize cancer diagnostics, cardiovascular diagnostics, and infectious disease diagnostics, requiring standardized protocols, clinical validation, and regulatory readiness. Drug discovery and development efforts concentrate on biomarker discovery, target validation, and toxicology studies, where reproducibility, cross-laboratory comparability, and integration with other preclinical datasets are paramount. End-user segmentation further clarifies operational demands and purchasing behaviors, encompassing academic and research institutes, contract research organizations, diagnostic laboratories, and pharmaceutical and biotechnology companies, each with unique procurement cycles, validation thresholds, and service expectations. Recognizing how these segments intersect enables providers to align product design, support services, and commercialization pathways to specific customer needs and regulatory timelines.

Regional strategic perspectives highlighting how Americas, Europe Middle East & Africa, and Asia-Pacific each shape adoption, regulatory strategy, and commercialization pathways

Regional dynamics materially influence the adoption, commercialization, and operational execution of microRNA initiatives. In the Americas, strong academic networks, a robust biotech industry, and active clinical trial infrastructures accelerate translational projects, but organizations must navigate evolving reimbursement frameworks and supply chain contingencies. Europe, Middle East & Africa presents a heterogeneous landscape where advanced regulatory ecosystems and public health priorities coexist with variable manufacturing capacity and procurement practices; opportunities often arise from pan-European consortia and region-wide clinical validation initiatives that harmonize standards. Asia-Pacific demonstrates rapid technology uptake, significant investment in local manufacturing, and growing diagnostic service networks, yet stakeholders contend with diverse regulatory approaches and competitive local suppliers that can influence partnership strategies.

These regional contours affect where companies prioritize regulatory submissions, localized manufacturing investments, and strategic partnerships. For example, adoption timelines tend to be fastest where clinical infrastructure and reimbursement pathways are mature, whereas markets with emerging diagnostic networks may favor lower-cost, high-throughput platforms and decentralized workflows. Cross-border research collaborations and multicenter clinical studies remain essential mechanisms for generating broadly relevant evidence, and regional policy shifts-particularly around data governance, import tariffs, and laboratory accreditation-can accelerate or constrain planned rollouts. Effective regional strategies therefore balance centralized validation efforts with localized commercialization plans that reflect regulatory, reimbursement, and supply chain realities.

Competitive and collaborative company-level dynamics showing how platform performance, reagent quality, bioinformatics capabilities, and service integration determine success in microRNA initiatives

Competitive dynamics within the microRNA ecosystem reflect a blend of established instrument manufacturers, agile reagent innovators, specialized bioinformatics houses, and integrated service providers. Instrument vendors differentiate through analytical performance characteristics such as sensitivity, dynamic range, and throughput, while reagent developers compete on robustness, lot-to-lot consistency, and ease of integration into automated workflows. Software and services providers create value by offering validated pipelines, regulatory-ready documentation, and interpretive layers that turn complex datasets into clinically meaningful outputs. Simultaneously, contract research organizations and diagnostic laboratories are consolidating capabilities around end-to-end service offerings that accelerate validation and market entry for translational assays.

Strategic activity in the sector tends to focus on pairing complementary strengths: platform vendors seek partnerships with kit and reagent specialists to deliver validated workflows; bioinformatics firms collaborate with clinical labs to refine algorithms under real-world conditions; and pharmaceutical companies engage with external service providers to de-risk biomarker discovery and validation efforts. These patterns favor organizations that can demonstrate interoperability, regulatory diligence, and scalability. Additionally, firms that invest in standardized data models and transparent validation practices are better positioned to support cross-institutional studies and to meet the evidentiary demands of clinicians and payers alike.

Actionable strategic recommendations for leaders to build supply chain resilience, deploy modular workflows, prioritize bioinformatics, and accelerate regulatory-ready validation

Industry leaders should adopt a pragmatic, multi-pronged strategy that balances near-term resilience with long-term value creation. First, expand supply chain resilience by qualifying multiple suppliers for critical components, exploring regional manufacturing partnerships, and maintaining strategic safety stocks for high-priority reagents and consumables. Second, prioritize investments in modular, standards-compliant workflows that allow rapid switching between instrument platforms and reagent chemistries, thereby reducing vendor lock-in and accelerating validation across sites. Third, strengthen bioinformatics and data management capabilities by adopting interoperable data standards, investing in reproducible pipelines, and building clinical-grade reporting modules that facilitate regulatory submissions and clinician adoption.

Further actions include deepening partnerships across academia, clinical laboratories, and industry to co-develop validation studies that meet both scientific and regulatory needs, and implementing flexible commercial models such as reagent-as-a-service or subscription-based analytics to align incentives with end users. Finally, reassess pricing and contracting frameworks to reflect tariff-driven cost dynamics while transparently communicating value through evidence of clinical utility and operational efficiency. Together, these measures help organizations protect margins, preserve innovation velocity, and improve the probability of successful clinical translation and commercialization.

Robust mixed-methods research methodology combining literature synthesis, expert interviews, performance validation, and triangulation to ensure defensible and actionable conclusions

The research methodology underpinning this analysis combined a structured review of primary scientific literature, targeted interviews with domain experts across academia, industry, and clinical laboratories, and cross-validation of technology performance characteristics against independent validation reports and regulatory guidance documents. The approach included systematic mapping of instrument capabilities, reagent performance parameters, and software interoperability, followed by scenario analysis to evaluate operational impacts under alternative procurement and regulatory conditions. Wherever possible, findings were triangulated across multiple evidence streams to ensure robustness and to surface consistent patterns rather than one-off observations.

Quality assurance measures encompassed validation of technical claims against independent assay performance data, review of clinical trial registries for translational evidence, and consultations with laboratory directors and procurement leads to ground results in operational realities. The methodology emphasized transparency in assumptions, reproducibility of analytic steps, and the use of standard definitions for key terms such as analytical sensitivity, specificity, and clinical validation, thereby ensuring that conclusions remain actionable and defensible for decision-makers across research, diagnostic, and commercial functions.

Conclusive synthesis emphasizing how technological advances, operational agility, and strategic partnerships converge to unlock microRNA's translational and commercial potential

In conclusion, the microRNA landscape stands at an inflection point where scientific maturity, technological capability, and commercial opportunity intersect. Advances in detection technologies, sequencing depth, and computational analytics are enabling higher-confidence biomarker discovery and more reliable diagnostic development, while changing procurement and regulatory environments demand greater operational agility. Stakeholders that proactively adapt to supply chain disruptions, prioritize interoperable and validated workflows, and invest in clinical-grade bioinformatics will be well positioned to translate scientific insights into validated diagnostics and therapeutics.

The imperative for leaders is clear: align technical roadmaps with regulatory and reimbursement realities, cultivate partnerships that accelerate validation across diverse sample types and use cases, and implement procurement and commercial strategies that mitigate tariff and supply risks. By doing so, organizations can preserve innovation momentum, reduce time-to-clinical-impact, and capture the tangible benefits of microRNA science for patients and research communities.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. microRNA Market, by Product Type

  • 8.1. Instruments
    • 8.1.1. Microarray Systems
    • 8.1.2. qPCR Systems
    • 8.1.3. Sequencing Systems
  • 8.2. Kits & Reagents
    • 8.2.1. Detection Kits
    • 8.2.2. Extraction Kits
    • 8.2.3. Library Prep Kits
    • 8.2.4. Profiling Kits
  • 8.3. Software & Services
    • 8.3.1. Bioinformatics Services
    • 8.3.2. Consultation Services
    • 8.3.3. Data Analysis Software

9. microRNA Market, by Technology

  • 9.1. Polymerase Chain Reaction
  • 9.2. Hybridization Based
    • 9.2.1. Microarray
    • 9.2.2. In Situ Hybridization
  • 9.3. Sequencing Based
    • 9.3.1. Next Generation Sequencing
    • 9.3.2. Single Molecule Sequencing
  • 9.4. Blotting And Electrophoresis
  • 9.5. Immunoassay And Reporter Technologies

10. microRNA Market, by Sample Source

  • 10.1. Tissue Samples
  • 10.2. Biofluids
    • 10.2.1. Blood
      • 10.2.1.1. Serum
      • 10.2.1.2. Plasma
    • 10.2.2. Urine
    • 10.2.3. Saliva
    • 10.2.4. Cerebrospinal Fluid
  • 10.3. Cell Lines
    • 10.3.1. Human Cell Lines
    • 10.3.2. Animal Cell Lines
    • 10.3.3. Primary Cells
  • 10.4. Exosomes And Extracellular Vesicles

11. microRNA Market, by Application

  • 11.1. Basic Research
    • 11.1.1. Functional Genomics
    • 11.1.2. Gene Expression Profiling
  • 11.2. Diagnostics
    • 11.2.1. Cancer Diagnostics
    • 11.2.2. Cardiovascular Diagnostics
    • 11.2.3. Infectious Disease Diagnostics
  • 11.3. Drug Discovery & Development
    • 11.3.1. Biomarker Discovery
    • 11.3.2. Target Validation
    • 11.3.3. Toxicology Studies

12. microRNA Market, by End User

  • 12.1. Academic & Research Institutes
  • 12.2. Contract Research Organizations
  • 12.3. Diagnostic Laboratories
  • 12.4. Pharmaceutical & Biotechnology Companies

13. microRNA Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. microRNA Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. microRNA Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States microRNA Market

17. China microRNA Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Agilent Technologies, Inc.
  • 18.6. BioGenex Laboratories, Inc.
  • 18.7. GeneCopoeia, Inc.
  • 18.8. Horizon Discovery Group plc
  • 18.9. Illumina, Inc.
  • 18.10. InteRNA Technologies B.V.
  • 18.11. Merck KGaA
  • 18.12. Miltenyi Biotec GmbH
  • 18.13. Mirxes Pte. Ltd.
  • 18.14. NanoString Technologies, Inc.
  • 18.15. New England Biolabs, Inc.
  • 18.16. OriGene Technologies, Inc.
  • 18.17. PerkinElmer, Inc.
  • 18.18. QIAGEN N.V.
  • 18.19. Quantabio, Inc.
  • 18.20. Regulus Therapeutics Inc.
  • 18.21. Takara Bio Inc.
  • 18.22. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL MICRORNA MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL MICRORNA MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL MICRORNA MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL MICRORNA MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL MICRORNA MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL MICRORNA MARKET SIZE, BY SAMPLE SOURCE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL MICRORNA MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL MICRORNA MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL MICRORNA MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL MICRORNA MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL MICRORNA MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES MICRORNA MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA MICRORNA MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL MICRORNA MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL MICRORNA MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL MICRORNA MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL MICRORNA MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL MICRORNA MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL MICRORNA MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL MICRORNA MARKET SIZE, BY MICROARRAY SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL MICRORNA MARKET SIZE, BY MICROARRAY SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL MICRORNA MARKET SIZE, BY MICROARRAY SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL MICRORNA MARKET SIZE, BY QPCR SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL MICRORNA MARKET SIZE, BY QPCR SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL MICRORNA MARKET SIZE, BY QPCR SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL MICRORNA MARKET SIZE, BY SEQUENCING SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL MICRORNA MARKET SIZE, BY SEQUENCING SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL MICRORNA MARKET SIZE, BY SEQUENCING SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL MICRORNA MARKET SIZE, BY KITS & REAGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL MICRORNA MARKET SIZE, BY KITS & REAGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL MICRORNA MARKET SIZE, BY KITS & REAGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL MICRORNA MARKET SIZE, BY KITS & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL MICRORNA MARKET SIZE, BY DETECTION KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL MICRORNA MARKET SIZE, BY DETECTION KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL MICRORNA MARKET SIZE, BY DETECTION KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL MICRORNA MARKET SIZE, BY EXTRACTION KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL MICRORNA MARKET SIZE, BY EXTRACTION KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL MICRORNA MARKET SIZE, BY EXTRACTION KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL MICRORNA MARKET SIZE, BY LIBRARY PREP KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL MICRORNA MARKET SIZE, BY LIBRARY PREP KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL MICRORNA MARKET SIZE, BY LIBRARY PREP KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL MICRORNA MARKET SIZE, BY PROFILING KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL MICRORNA MARKET SIZE, BY PROFILING KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL MICRORNA MARKET SIZE, BY PROFILING KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL MICRORNA MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL MICRORNA MARKET SIZE, BY SOFTWARE & SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL MICRORNA MARKET SIZE, BY SOFTWARE & SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL MICRORNA MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL MICRORNA MARKET SIZE, BY BIOINFORMATICS SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL MICRORNA MARKET SIZE, BY BIOINFORMATICS SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL MICRORNA MARKET SIZE, BY BIOINFORMATICS SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL MICRORNA MARKET SIZE, BY CONSULTATION SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL MICRORNA MARKET SIZE, BY CONSULTATION SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL MICRORNA MARKET SIZE, BY CONSULTATION SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL MICRORNA MARKET SIZE, BY DATA ANALYSIS SOFTWARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL MICRORNA MARKET SIZE, BY DATA ANALYSIS SOFTWARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL MICRORNA MARKET SIZE, BY DATA ANALYSIS SOFTWARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL MICRORNA MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL MICRORNA MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL MICRORNA MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL MICRORNA MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL MICRORNA MARKET SIZE, BY HYBRIDIZATION BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL MICRORNA MARKET SIZE, BY HYBRIDIZATION BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL MICRORNA MARKET SIZE, BY HYBRIDIZATION BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL MICRORNA MARKET SIZE, BY HYBRIDIZATION BASED, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL MICRORNA MARKET SIZE, BY MICROARRAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL MICRORNA MARKET SIZE, BY MICROARRAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL MICRORNA MARKET SIZE, BY MICROARRAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL MICRORNA MARKET SIZE, BY IN SITU HYBRIDIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL MICRORNA MARKET SIZE, BY IN SITU HYBRIDIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL MICRORNA MARKET SIZE, BY IN SITU HYBRIDIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL MICRORNA MARKET SIZE, BY SEQUENCING BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL MICRORNA MARKET SIZE, BY SEQUENCING BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL MICRORNA MARKET SIZE, BY SEQUENCING BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL MICRORNA MARKET SIZE, BY SEQUENCING BASED, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL MICRORNA MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL MICRORNA MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL MICRORNA MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL MICRORNA MARKET SIZE, BY SINGLE MOLECULE SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL MICRORNA MARKET SIZE, BY SINGLE MOLECULE SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL MICRORNA MARKET SIZE, BY SINGLE MOLECULE SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL MICRORNA MARKET SIZE, BY BLOTTING AND ELECTROPHORESIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL MICRORNA MARKET SIZE, BY BLOTTING AND ELECTROPHORESIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL MICRORNA MARKET SIZE, BY BLOTTING AND ELECTROPHORESIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL MICRORNA MARKET SIZE, BY IMMUNOASSAY AND REPORTER TECHNOLOGIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL MICRORNA MARKET SIZE, BY IMMUNOASSAY AND REPORTER TECHNOLOGIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL MICRORNA MARKET SIZE, BY IMMUNOASSAY AND REPORTER TECHNOLOGIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL MICRORNA MARKET SIZE, BY SAMPLE SOURCE, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL MICRORNA MARKET SIZE, BY TISSUE SAMPLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL MICRORNA MARKET SIZE, BY TISSUE SAMPLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL MICRORNA MARKET SIZE, BY TISSUE SAMPLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL MICRORNA MARKET SIZE, BY BIOFLUIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL MICRORNA MARKET SIZE, BY BIOFLUIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL MICRORNA MARKET SIZE, BY BIOFLUIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL MICRORNA MARKET SIZE, BY BIOFLUIDS, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL MICRORNA MARKET SIZE, BY BLOOD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL MICRORNA MARKET SIZE, BY BLOOD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL MICRORNA MARKET SIZE, BY BLOOD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL MICRORNA MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL MICRORNA MARKET SIZE, BY SERUM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL MICRORNA MARKET SIZE, BY SERUM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL MICRORNA MARKET SIZE, BY SERUM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL MICRORNA MARKET SIZE, BY PLASMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL MICRORNA MARKET SIZE, BY PLASMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL MICRORNA MARKET SIZE, BY PLASMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL MICRORNA MARKET SIZE, BY URINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL MICRORNA MARKET SIZE, BY URINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL MICRORNA MARKET SIZE, BY URINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL MICRORNA MARKET SIZE, BY SALIVA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL MICRORNA MARKET SIZE, BY SALIVA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL MICRORNA MARKET SIZE, BY SALIVA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL MICRORNA MARKET SIZE, BY CEREBROSPINAL FLUID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL MICRORNA MARKET SIZE, BY CEREBROSPINAL FLUID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL MICRORNA MARKET SIZE, BY CEREBROSPINAL FLUID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL MICRORNA MARKET SIZE, BY CELL LINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL MICRORNA MARKET SIZE, BY CELL LINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL MICRORNA MARKET SIZE, BY CELL LINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL MICRORNA MARKET SIZE, BY CELL LINES, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL MICRORNA MARKET SIZE, BY HUMAN CELL LINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL MICRORNA MARKET SIZE, BY HUMAN CELL LINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL MICRORNA MARKET SIZE, BY HUMAN CELL LINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL MICRORNA MARKET SIZE, BY ANIMAL CELL LINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL MICRORNA MARKET SIZE, BY ANIMAL CELL LINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL MICRORNA MARKET SIZE, BY ANIMAL CELL LINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL MICRORNA MARKET SIZE, BY PRIMARY CELLS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL MICRORNA MARKET SIZE, BY PRIMARY CELLS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL MICRORNA MARKET SIZE, BY PRIMARY CELLS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL MICRORNA MARKET SIZE, BY EXOSOMES AND EXTRACELLULAR VESICLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL MICRORNA MARKET SIZE, BY EXOSOMES AND EXTRACELLULAR VESICLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL MICRORNA MARKET SIZE, BY EXOSOMES AND EXTRACELLULAR VESICLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL MICRORNA MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL MICRORNA MARKET SIZE, BY BASIC RESEARCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL MICRORNA MARKET SIZE, BY BASIC RESEARCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL MICRORNA MARKET SIZE, BY BASIC RESEARCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL MICRORNA MARKET SIZE, BY BASIC RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL MICRORNA MARKET SIZE, BY FUNCTIONAL GENOMICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL MICRORNA MARKET SIZE, BY FUNCTIONAL GENOMICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL MICRORNA MARKET SIZE, BY FUNCTIONAL GENOMICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL MICRORNA MARKET SIZE, BY GENE EXPRESSION PROFILING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL MICRORNA MARKET SIZE, BY GENE EXPRESSION PROFILING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL MICRORNA MARKET SIZE, BY GENE EXPRESSION PROFILING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL MICRORNA MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL MICRORNA MARKET SIZE, BY DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL MICRORNA MARKET SIZE, BY DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL MICRORNA MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL MICRORNA MARKET SIZE, BY CANCER DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL MICRORNA MARKET SIZE, BY CANCER DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL MICRORNA MARKET SIZE, BY CANCER DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL MICRORNA MARKET SIZE, BY CARDIOVASCULAR DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL MICRORNA MARKET SIZE, BY CARDIOVASCULAR DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL MICRORNA MARKET SIZE, BY CARDIOVASCULAR DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL MICRORNA MARKET SIZE, BY INFECTIOUS DISEASE DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL MICRORNA MARKET SIZE, BY INFECTIOUS DISEASE DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL MICRORNA MARKET SIZE, BY INFECTIOUS DISEASE DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL MICRORNA MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL MICRORNA MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL MICRORNA MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL MICRORNA MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL MICRORNA MARKET SIZE, BY BIOMARKER DISCOVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL MICRORNA MARKET SIZE, BY BIOMARKER DISCOVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL MICRORNA MARKET SIZE, BY BIOMARKER DISCOVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL MICRORNA MARKET SIZE, BY TARGET VALIDATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL MICRORNA MARKET SIZE, BY TARGET VALIDATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL MICRORNA MARKET SIZE, BY TARGET VALIDATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL MICRORNA MARKET SIZE, BY TOXICOLOGY STUDIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL MICRORNA MARKET SIZE, BY TOXICOLOGY STUDIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL MICRORNA MARKET SIZE, BY TOXICOLOGY STUDIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL MICRORNA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL MICRORNA MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL MICRORNA MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL MICRORNA MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL MICRORNA MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL MICRORNA MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL MICRORNA MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL MICRORNA MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 163. GLOBAL MICRORNA MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL MICRORNA MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL MICRORNA MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 166. GLOBAL MICRORNA MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL MICRORNA MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 168. GLOBAL MICRORNA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 169. AMERICAS MICRORNA MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 170. AMERICAS MICRORNA MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 171. AMERICAS MICRORNA MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 172. AMERICAS MICRORNA MARKET SIZE, BY KITS & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 173. AMERICAS MICRORNA MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 174. AMERICAS MICRORNA MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 175. AMERICAS MICRORNA MARKET SIZE, BY HYBRIDIZATION BASED, 2018-2032 (USD MILLION)
  • TABLE 176. AMERICAS MICRORNA MARKET SIZE, BY SEQUENCING BASED, 2018-2032 (USD MILLION)
  • TABLE 177. AMERICAS MICRORNA MARKET SIZE, BY SAMPLE SOURCE, 2018-2032 (USD MILLION)
  • TABLE 178. AMERICAS MICRORNA MARKET SIZE, BY BIOFLUIDS, 2018-2032 (USD MILLION)
  • TABLE 179. AMERICAS MICRORNA MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 180. AMERICAS MICRORNA MARKET SIZE, BY CELL LINES, 2018-2032 (USD MILLION)
  • TABLE 181. AMERICAS MICRORNA MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 182. AMERICAS MICRORNA MARKET SIZE, BY BASIC RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 183. AMERICAS MICRORNA MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 184. AMERICAS MICRORNA MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 185. AMERICAS MICRORNA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 186. NORTH AMERICA MICRORNA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 187. NORTH AMERICA MICRORNA MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. NORTH AMERICA MICRORNA MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 189. NORTH AMERICA MICRORNA MARKET SIZE, BY KITS & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 190. NORTH AMERICA MICRORNA MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 191. NORTH AMERICA MICRORNA MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 192. NORTH AMERICA MICRORNA MARKET SIZE, BY HYBRIDIZATION BASED, 2018-2032 (USD MILLION)
  • TABLE 193. NORTH AMERICA MICRORNA MARKET SIZE, BY SEQUENCING BASED, 2018-2032 (USD MILLION)
  • TABLE 194. NORTH AMERICA MICRORNA MARKET SIZE, BY SAMPLE SOURCE, 2018-2032 (USD MILLION)
  • TABLE 195. NORTH AMERICA MICRORNA MARKET SIZE, BY BIOFLUIDS, 2018-2032 (USD MILLION)
  • TABLE 196. NORTH AMERICA MICRORNA MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 197. NORTH AMERICA MICRORNA MARKET SIZE, BY CELL LINES, 2018-2032 (USD MILLION)
  • TABLE 198. NORTH AMERICA MICRORNA MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 199. NORTH AMERICA MICRORNA MARKET SIZE, BY BASIC RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 200. NORTH AMERICA MICRORNA MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 201. NORTH AMERICA MICRORNA MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 202. NORTH AMERICA MICRORNA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 203. LATIN AMERICA MICRORNA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 204. LATIN AMERICA MICRORNA MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 205. LATIN AMERICA MICRORNA MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 206. LATIN AMERICA MICRORNA MARKET SIZE, BY KITS & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 207. LATIN AMERICA MICRORNA MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 208. LATIN AMERICA MICRORNA MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 209. LATIN AMERICA MICRORNA MARKET SIZE, BY HYBRIDIZATION BASED, 2018-2032 (USD MILLION)
  • TABLE 210. LATIN AMERICA MICRORNA MARKET SIZE, BY SEQUENCING BASED, 2018-2032 (USD MILLION)
  • TABLE 211. LATIN AMERICA MICRORNA MARKET SIZE, BY SAMPLE SOURCE, 2018-2032 (USD MILLION)
  • TABLE 212. LATIN AMERICA MICRORNA MARKET SIZE, BY BIOFLUIDS, 2018-2032 (USD MILLION)
  • TABLE 213. LATIN AMERICA MICRORNA MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 214. LATIN AMERICA MICRORNA MARKET SIZE, BY CELL LINES, 2018-2032 (USD MILLION)
  • TABLE 215. LATIN AMERICA MICRORNA MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 216. LATIN AMERICA MICRORNA MARKET SIZE, BY BASIC RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 217. LATIN AMERICA MICRORNA MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 218. LATIN AMERICA MICRORNA MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 219. LATIN AMERICA MICRORNA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA MICRORNA MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPE, MIDDLE EAST & AFRICA MICRORNA MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPE, MIDDLE EAST & AFRICA MICRORNA MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPE, MIDDLE EAST & AFRICA MICRORNA MARKET SIZE, BY KITS & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPE, MIDDLE EAST & AFRICA MICRORNA MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPE, MIDDLE EAST & AFRICA MICRORNA MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPE, MIDDLE EAST & AFRICA MICRORNA MARKET SIZE, BY HYBRIDIZATION BASED, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPE, MIDDLE EAST & AFRICA MICRORNA MARKET SIZE, BY SEQUENCING BASED, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPE, MIDDLE EAST & AFRICA MICRORNA MARKET SIZE, BY SAMPLE SOURCE, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPE, MIDDLE EAST & AFRICA MICRORNA MARKET SIZE, BY BIOFLUIDS, 2018-2032 (USD MILLION)
  • TABLE 230. EUROPE, MIDDLE EAST & AFRICA MICRORNA MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 231. EUROPE, MIDDLE EAST & AFRICA MICRORNA MARKET SIZE, BY CELL LINES, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPE, MIDDLE EAST & AFRICA MICRORNA MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPE, MIDDLE EAST & AFRICA MICRORNA MARKET SIZE, BY BASIC RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 234. EUROPE, MIDDLE EAST & AFRICA MICRORNA MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 235. EUROPE, MIDDLE EAST & AFRICA MICRORNA MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 236. EUROPE, MIDDLE EAST & AFRICA MICRORNA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 237. EUROPE MICRORNA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 238. EUROPE MICRORNA MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 239. EUROPE MICRORNA MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 240. EUROPE MICRORNA MARKET SIZE, BY KITS & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 241. EUROPE MICRORNA MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 242. EUROPE MICRORNA MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 243. EUROPE MICRORNA MARKET SIZE, BY HYBRIDIZATION BASED, 2018-2032 (USD MILLION)
  • TABLE 244. EUROPE MICRORNA MARKET SIZE, BY SEQUENCING BASED, 2018-2032 (USD MILLION)
  • TABLE 245. EUROPE MICRORNA MARKET SIZE, BY SAMPLE SOURCE, 2018-2032 (USD MILLION)
  • TABLE 246. EUROPE MICRORNA MARKET SIZE, BY BIOFLUIDS, 2018-2032 (USD MILLION)
  • TABLE 247. EUROPE MICRORNA MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 248. EUROPE MICRORNA MARKET SIZE, BY CELL LINES, 2018-2032 (USD MILLION)
  • TABLE 249. EUROPE MICRORNA MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 250. EUROPE MICRORNA MARKET SIZE, BY BASIC RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 251. EUROPE MICRORNA MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 252. EUROPE MICRORNA MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 253. EUROPE MICRORNA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 254. MIDDLE EAST MICRORNA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 255. MIDDLE EAST MICRORNA MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 256. MIDDLE EAST MICRORNA MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 257. MIDDLE EAST MICRORNA MARKET SIZE, BY KITS & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 258. MIDDLE EAST MICRORNA MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 259. MIDDLE EAST MICRORNA MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 260. MIDDLE EAST MICRORNA MARKET SIZE, BY HYBRIDIZATION BASED, 2018-2032 (USD MILLION)
  • TABLE 261. MIDDLE EAST MICRORNA MARKET SIZE, BY SEQUENCING BASED, 2018-2032 (USD MILLION)
  • TABLE 262. MIDDLE EAST MICRORNA MARKET SIZE, BY SAMPLE SOURCE, 2018-2032 (USD MILLION)
  • TABLE 263. MIDDLE EAST MICRORNA MARKET SIZE, BY BIOFLUIDS, 2018-2032 (USD MILLION)
  • TABLE 264. MIDDLE EAST MICRORNA MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 265. MIDDLE EAST MICRORNA MARKET SIZE, BY CELL LINES, 2018-2032 (USD MILLION)
  • TABLE 266. MIDDLE EAST MICRORNA MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 267. MIDDLE EAST MICRORNA MARKET SIZE, BY BASIC RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 268. MIDDLE EAST MICRORNA MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 269. MIDDLE EAST MICRORNA MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 270. MIDDLE EAST MICRORNA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 271. AFRICA MICRORNA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 272. AFRICA MICRORNA MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 273. AFRICA MICRORNA MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 274. AFRICA MICRORNA MARKET SIZE, BY KITS & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 275. AFRICA MICRORNA MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 276. AFRICA MICRORNA MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 277. AFRICA MICRORNA MARKET SIZE, BY HYBRIDIZATION BASED, 2018-2032 (USD MILLION)
  • TABLE 278. AFRICA MICRORNA MARKET SIZE, BY SEQUENCING BASED, 2018-2032 (USD MILLION)
  • TABLE 279. AFRICA MICRORNA MARKET SIZE, BY SAMPLE SOURCE, 2018-2032 (USD MILLION)
  • TABLE 280. AFRICA MICRORNA MARKET SIZE, BY BIOFLUIDS, 2018-2032 (USD MILLION)
  • TABLE 281. AFRICA MICRORNA MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 282. AFRICA MICRORNA MARKET SIZE, BY CELL LINES, 2018-2032 (USD MILLION)
  • TABLE 283. AFRICA MICRORNA MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 284. AFRICA MICRORNA MARKET SIZE, BY BASIC RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 285. AFRICA MICRORNA MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 286. AFRICA MICRORNA MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 287. AFRICA MICRORNA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 288. ASIA-PACIFIC MICRORNA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 289. ASIA-PACIFIC MICRORNA MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 290. ASIA-PACIFIC MICRORNA MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 291. ASIA-PACIFIC MICRORNA MARKET SIZE, BY KITS & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 292. ASIA-PACIFIC MICRORNA MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 293. ASIA-PACIFIC MICRORNA MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 294. ASIA-PACIFIC MICRORNA MARKET SIZE, BY HYBRIDIZATION BASED, 2018-2032 (USD MILLION)
  • TABLE 295. ASIA-PACIFIC MICRORNA MARKET SIZE, BY SEQUENCING BASED, 2018-2032 (USD MILLION)
  • TABLE 296. ASIA-PACIFIC MICRORNA MARKET SIZE, BY SAMPLE SOURCE, 2018-2032 (USD MILLION)
  • TABLE 297. ASIA-PACIFIC MICRORNA MARKET SIZE, BY BIOFLUIDS, 2018-2032 (USD MILLION)
  • TABLE 298. ASIA-PACIFIC MICRORNA MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 299. ASIA-PACIFIC MICRORNA MARKET SIZE, BY CELL LINES, 2018-2032 (USD MILLION)
  • TABLE 300. ASIA-PACIFIC MICRORNA MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 301. ASIA-PACIFIC MICRORNA MARKET SIZE, BY BASIC RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 302. ASIA-PACIFIC MICRORNA MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 303. ASIA-PACIFIC MICRORNA MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 304. ASIA-PACIFIC MICRORNA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 305. GLOBAL MICRORNA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 306. ASEAN MICRORNA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 307. ASEAN MICRORNA MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 308. ASEAN MICRORNA MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 309. ASEAN MICRORNA MARKET SIZE, BY KITS & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 310. ASEAN MICRORNA MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 311. ASEAN MICRORNA MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 312. ASEAN MICRORNA MARKET SIZE, BY HYBRIDIZATION BASED, 2018-2032 (USD MILLION)
  • TABLE 313. ASEAN MICRORNA MARKET SIZE, BY SEQUENCING BASED, 2018-2032 (USD MILLION)
  • TABLE 314. ASEAN MICRORNA MARKET SIZE, BY SAMPLE SOURCE, 2018-2032 (USD MILLION)
  • TABLE 315. ASEAN MICRORNA MARKET SIZE, BY BIOFLUIDS, 2018-2032 (USD MILLION)
  • TABLE 316. ASEAN MICRORNA MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 317. ASEAN MICRORNA MARKET SIZE, BY CELL LINES, 2018-2032 (USD MILLION)
  • TABLE 318. ASEAN MICRORNA MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 319. ASEAN MICRORNA MARKET SIZE, BY BASIC RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 320. ASEAN MICRORNA MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 321. ASEAN MICRORNA MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 322. ASEAN MICRORNA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 323. GCC MICRORNA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 324. GCC MICRORNA MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 325. GCC MICRORNA MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 326. GCC MICRORNA MARKET SIZE, BY KITS & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 327. GCC MICRORNA MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 328. GCC MICRORNA MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 329. GCC MICRORNA MARKET SIZE, BY HYBRIDIZATION BASED, 2018-2032 (USD MILLION)
  • TABLE 330. GCC MICRORNA MARKET SIZE, BY SEQUENCING BASED, 2018-2032 (USD MILLION)
  • TABLE 331. GCC MICRORNA MARKET SIZE, BY SAMPLE SOURCE, 2018-2032 (USD MILLION)
  • TABLE 332. GCC MICRORNA MARKET SIZE, BY BIOFLUIDS, 2018-2032 (USD MILLION)
  • TABLE 333. GCC MICRORNA MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 334. GCC MICRORNA MARKET SIZE, BY CELL LINES, 2018-2032 (USD MILLION)
  • TABLE 335. GCC MICRORNA MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 336. GCC MICRORNA MARKET SIZE, BY BASIC RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 337. GCC MICRORNA MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 338. GCC MICRORNA MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 339. GCC MICRORNA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 340. EUROPEAN UNION MICRORNA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 341. EUROPEAN UNION MICRORNA MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 342. EUROPEAN UNION MICRORNA MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 343. EUROPEAN UNION MICRORNA MARKET SIZE, BY KITS & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 344. EUROPEAN UNION MICRORNA MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 345. EUROPEAN UNION MICRORNA MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 346. EUROPEAN UNION MICRORNA MARKET SIZE, BY HYBRIDIZATION BASED, 2018-2032 (USD MILLION)
  • TABLE 347. EUROPEAN UNION MICRORNA MARKET SIZE, BY SEQUENCING BASED, 2018-2032 (USD MILLION)
  • TABLE 348. EUROPEAN UNION MICRORNA MARKET SIZE, BY SAMPLE SOURCE, 2018-2032 (USD MILLION)
  • TABLE 349. EUROPEAN UNION MICRORNA MARKET SIZE, BY BIOFLUIDS, 2018-2032 (USD MILLION)
  • TABLE 350. EUROPEAN UNION MICRORNA MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 351. EUROPEAN UNION MICRORNA MARKET SIZE, BY CELL LINES, 2018-2032 (USD MILLION)
  • TABLE 352. EUROPEAN UNION MICRORNA MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 353. EUROPEAN UNION MICRORNA MARKET SIZE, BY BASIC RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 354. EUROPEAN UNION MICRORNA MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 355. EUROPEAN UNION MICRORNA MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 356. EUROPEAN UNION MICRORNA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 357. BRICS MICRORNA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 358. BRICS MICRORNA MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 359. BRICS MICRORNA MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 360. BRICS MICRORNA MARKET SIZE, BY KITS & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 361. BRI